• Should medical device companies have to anticipate doctor misuse when fashioning warnings? One court says yes (Drug & Device Law)
  • Puzzling mixed bag in federal court ruling involving FDA regulation of green tea health claim (FDA Law Blog)
  • Health care fraud enforcement rakes in the bucks for the federal government (Original Source)
  • Proxy season update: recent SEC actions on “no-action” letter requests from public companies (CorporateCounsel.net)
  • California state attorney general steps into the privacy fray through agreement with mobile app makers (Law Across the Wire and Into the Cloud)
  • “Failure to update label” claims circumvent federal generic drug preemption defenses (Product Liability Monitor)
  • No live TV for six hours of ObamaCare arguments at the Supreme Court, but same day transcripts! (The Hill’s Healthwatch)
  • EPA to reduce incentives to self-report regulatory violations? (Corporate Environmental Lawyer)